Anixa Biosciences Inc (NASDAQ:ANIX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have received an average recommendation of “Hold” from the five analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $8.50.

A number of equities analysts have recently weighed in on ANIX shares. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 19th. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Wall Street Zen upgraded Anixa Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 20th. Finally, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $3.28 on Wednesday. The business’s fifty day moving average price is $3.33 and its two-hundred day moving average price is $2.98. The stock has a market cap of $111.59 million, a PE ratio of -10.58 and a beta of 0.51. Anixa Biosciences has a one year low of $2.32 and a one year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. As a group, equities research analysts predict that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Anixa Biosciences news, CEO Amit Kumar bought 21,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The stock was purchased at an average cost of $2.50 per share, for a total transaction of $52,500.00. Following the completion of the purchase, the chief executive officer owned 630,812 shares of the company’s stock, valued at $1,577,030. This trade represents a 3.44% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders acquired 50,024 shares of company stock valued at $148,971 in the last ninety days. Corporate insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Anixa Biosciences

Institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC acquired a new stake in shares of Anixa Biosciences during the 2nd quarter worth $33,000. Sanctuary Advisors LLC acquired a new position in Anixa Biosciences in the second quarter valued at $29,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Anixa Biosciences during the second quarter valued at about $29,000. Cetera Investment Advisers purchased a new stake in Anixa Biosciences during the fourth quarter valued at about $35,000. Finally, Benjamin Edwards Inc. acquired a new stake in Anixa Biosciences during the second quarter worth about $37,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.